# Rigel Pharmaceuticals clinical trials: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with Rigel Pharmaceuticals as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Rigel Pharmaceuticals: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/rigel-pharmaceuticals

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 15, 2026 | NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Phase 4 | Recruiting | NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer, Solid Tumor Malignancies, Advanced Malignancies | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704658) |
| March 20, 2026 | NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | Rigel Pharmaceuticals | Phase 4 | Recruiting | AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486713) |
| December 8, 2023 | NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | Rigel Pharmaceuticals | Phase 2 | Recruiting | High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06161974) |
| April 4, 2022 | NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Rigel Pharmaceuticals | Phase 1/2 | Recruiting | Low Risk Myelodysplastic Syndromes | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05308264) |
| May 27, 2021 | NCT04904276 | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response... | Rigel Pharmaceuticals | Observational | Terminated | ITP, Immune Thrombocytopenia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04904276) |
| November 16, 2020 | NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19... | Rigel Pharmaceuticals | Phase 3 | Completed | Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04629703) |
| October 25, 2019 | NCT04138927 | A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia | Rigel Pharmaceuticals | Phase 3 | Enrolling by invitation | Warm Antibody Autoimmune Hemolytic Anemia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04138927) |
| December 5, 2018 | NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | Rigel Pharmaceuticals | Phase 3 | Completed | Warm Antibody Autoimmune Hemolytic Anemia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03764618) |
| December 6, 2017 | NCT03363334 | Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP | Rigel Pharmaceuticals | Not applicable | No longer available | Immune Thrombocytopenic Purpura | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03363334) |
| November 24, 2015 | NCT02612558 | A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) | Rigel Pharmaceuticals | Phase 2 | Completed | Warm Antibody Autoimmune Hemolytic Anemia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02612558) |
| May 4, 2015 | NCT02433236 | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy | Rigel Pharmaceuticals | Phase 2 | Withdrawn | IGA Nephropathy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02433236) |
| April 14, 2014 | NCT02112838 | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy | Rigel Pharmaceuticals | Phase 2 | Completed | IGA Nephropathy | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02112838) |
| March 4, 2014 | NCT02077192 | Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | Rigel Pharmaceuticals | Phase 3 | Completed | Immune Thrombocytopenic Purpura | 123 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02077192) |
| March 3, 2014 | NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | Rigel Pharmaceuticals | Phase 3 | Completed | Immune Thrombocytopenic Purpura | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02076412) |
| March 3, 2014 | NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) | Rigel Pharmaceuticals | Phase 3 | Completed | Immune Thrombocytopenic Purpura | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02076399) |
| January 20, 2014 | NCT02040623 | Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) | Rigel Pharmaceuticals | Phase 2 | Completed | Chronic Graft-versus-host Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02040623) |
| July 16, 2013 | NCT01900249 | To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca | Rigel Pharmaceuticals | Phase 2 | Completed | Keratoconjunctivitis Sicca | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01900249) |
| November 27, 2012 | NCT01733992 | A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease | Rigel Pharmaceuticals | Phase 1 | Completed | Keratoconjunctivitis Sicca | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01733992) |
| May 11, 2012 | NCT01597050 | Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions | Rigel Pharmaceuticals | Phase 2 | Completed | Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01597050) |
| May 3, 2012 | NCT01591044 | A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma | Rigel Pharmaceuticals | Phase 2 | Completed | Asthma | 301 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01591044) |
| November 25, 2008 | NCT00798096 | Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma | Rigel Pharmaceuticals | Phase 2 | Completed | T Cell Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00798096) |
| September 16, 2008 | NCT00752999 | Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus | Rigel Pharmaceuticals | Phase 2 | Withdrawn | Systemic Lupus Erythematosus | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00752999) |
| June 27, 2008 | NCT00706342 | Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP) | Rigel Pharmaceuticals | Phase 2 | Completed | Purpura, Thrombocytopenic, Idiopathic | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00706342) |
| April 24, 2008 | NCT00665925 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis | Rigel Pharmaceuticals | Phase 2 | Completed | Rheumatoid Arthritis | 457 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00665925) |
| April 24, 2008 | NCT00665626 | Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) | Rigel Pharmaceuticals | Phase 2 | Completed | Rheumatoid Arthritis | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00665626) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 2 |
| Phase 2 | 15 |
| Phase 3 | 6 |
| Phase 4 | 2 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Recruiting | 4 |
| Withdrawn | 2 |
| No longer available | 1 |
| Enrolling by invitation | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Purpura, Thrombocytopenic, Idiopathic | 6 |
| Arthritis, Rheumatoid | 3 |
| Keratoconjunctivitis Sicca | 3 |
| Lupus Erythematosus, Systemic | 2 |
| Lymphoma | 2 |
| Glioma | 2 |
| Neoplasms | 2 |
| Glomerulonephritis, IGA | 2 |
| Lupus Erythematosus, Discoid | 1 |
| Myelodysplastic Syndromes | 1 |
| COVID-19 | 1 |
| Severe Acute Respiratory Syndrome | 1 |
| Pneumonia | 1 |
| Pneumonia, Viral | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma, Mantle-Cell | 1 |
| Rhinitis, Allergic, Seasonal | 1 |
| Rhinitis, Allergic | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Cholangiocarcinoma | 1 |
| Astrocytoma | 1 |
| Glioblastoma | 1 |
| Diffuse Intrinsic Pontine Glioma | 1 |
| Brain Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Meat wholesalers in the United States](https://specstream.ai/data/businesses/meat-wholesalers/united-states)
- [Cheesesteak restaurants in the United States](https://specstream.ai/data/businesses/cheesesteak-restaurants/united-states)
- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
- [Agricultural cooperatives in the United States](https://specstream.ai/data/businesses/agricultural-cooperatives/united-states)
